


Patient derived orthotopic xenografts model of liquid tumor

Flowchart of PDOX establishment using AML/ALL samples

LIDE developed a novel PDOX platform for liquid tumor establishment, which enables orthotopic injection of cancer cell suspension prepared from patients peripheral blood/bone marrow intrafemorally into the mice bone marrow, and engraftment of PDOX using mice spleen as tumor source for further in vitro/in vivo assay.



The list of liquid tumor models established by LIDE

| Model ID | Sex | Age | PDX pathology | PDX s.c. | PDOX i.f. |
|-----------------|--------|-----|----------------------|-----------|-----------|
| LD1-0041-362047 | Male | 51 | ALL | Available | Available |
| LD1-0041-362073 | Male | 64 | ALL | Available | Available |
| LD1-0041-362356 | Male | 53 | ALL | Available | Available |
| LD1-0041-362478 | Male | 15 | ALL | Available | Available |
| LD1-1041-362519 | Female | 38 | ALL | TBD | Available |
| LD1-0041-362021 | Male | 32 | ALL | TBD | Available |
| LD1-0040-361280 | Female | 38 | AML | Available | Available |
| LD1-0040-361293 | Female | 61 | AML | Available | Available |
| LD1-0040-362349 | Male | 23 | AML | Available | Available |
| LD1-0040-362384 | Male | 59 | AML | TBD | Available |
| LD1-0040-362030 | Female | 56 | AML | TBD | Available |
| LD1-0040-361780 | Male | 49 | AML | TBD | Available |
| LD1-0040-362224 | Male | 75 | AML | TBD | Available |
| LD1-0040-362369 | Male | 57 | AML | Available | Available |
| LD1-0040-362393 | Female | 57 | AML | Available | Available |
| LD1-0040-362499 | Male | 68 | AML | TBD | Available |
| LD1-0040-362575 | Female | 31 | AML | Available | Available |
| LD1-0026-362219 | Male | 24 | Burkitt's lymphoma | Available | TBD |
| LD2-0026-200614 | Male | / | CLL transit to DLBCL | Available | TBD |
| LD1-0026-362314 | Male | 51 | Mantle cell lymphoma | Available | TBD |
| LD1-0029-361915 | Male | 62 | Multiple myeloma | Available | TBD |
| LD1-0029-361847 | Male | 54 | Multiple myeloma | Available | TBD |
| LD1-0006-370728 | Male | 68 | Multiple myeloma | Available | TBD |

Validation and Application of PDOX in liquid tumor

1

FACS detection: the corresponding relationship of clinical and PDX

| Gene | Clinical result | PDX result | |
|-------|-----------------|------------|--------|
| | | Blood | Spleen |
| CD45 | + | + | + |
| CD33 | + | + | + |
| MPO | + | + | + |
| CD56 | + | + | + |
| CD117 | + | + | + |

2


Gene detection: the corresponding relationship of clinical and PDX

| Gene | Clinical result | PDX result | | | | |
|-------------|-----------------|-----------------|-----------------|---------|---------------------------------|---------------------|
| | | WES_Mut(AF) | RNA_Mut(AF) | RNA_TPM | RNA_TPM_zscore_GTE _x | RNA_TPM_zscore_TCGA |
| c-kit/D816V | - | - | - | 12.5 | 4.200862288 | -1.086434655 |
| CEBPA | - | - | - | 117.22 | 1.922675063 | 0.460406123 |
| NPM1exon12A | + | Trp288fs(0.312) | Trp288fs(0.355) | 1558.02 | 4.793047232 | 3.38832293 |
| FLT3/ITD | - | - | - | 146.78 | 2.790451315 | 0.758331842 |

3



detection of PDX chromosome

The results of cell karyotype analysis showed that the patient's karyotype was normal and the expression was 46,XX[CP20]



4

verification of SOC: the correlation between clinical medication history and PDX



Cytarabine or cladribine demonstrated completely tumor elimination in an AML PDX.

AML PDX model was inoculated orthotopically, and CD47 abs showed anti-cancer effect by completely inhibiting CD45+CD33+ cells in mice.